Do NOACs improve the benefit-risk profile compared to VKAs in atrial fibrillation patients with polypharmacy?
In atrial fibrillation patients with polypharmacy, NOACs offer a superior benefit-risk profile compared to traditional vitamin K antagonists.
Polypharmacy was associated with increased thromboembolic, bleeding, and mortality risks in AF patients. NOACs had better benefit-risk profiles than VKAs in patients with polypharmacy.
Grymonprez et al. (Tue,) studied this question.